Projects per year
Personal profile
Biography
Professor Howard Gurney is the Director of Clinical Trials for the Faculty of Medicine and Health Sciences at Macquarie University.
Professor Gurney has a firm background in clinical research and has subspecialty interests in urogenital cancers including prostate, bladder, testis and kidney cancer.
He has been the principal investigator for over 100 clinical trials and has published over 100 peer-reviewed articles in journals and book chapters. Current research interests include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area. He is regarded as a leading authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics.
Fingerprint
Dive into the research topics where Howard Gurney is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 6 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
-
Checkmate 914: A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Gurney, H., Chapman, N. & Zhang, A.
17/08/20 → 4/06/25
Project: Research
-
CN1-101: A phase I, open label, multi-center,dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma
Park, J., Chapman, N., Gurney, H. & Sabanathan, D.
3/08/20 → 30/06/25
Project: Research
-
CRC-P round 9: Manufacturing consortium for cancer radioimmunotherapy
Groth, A., Chandler, C., Adams, T., Walsh, B., Lengkeek, N., Chung, R., Gurney, H., Gillatt, D. & O'Meara, T.
1/07/20 → 30/06/23
Project: Research
-
Y-biologics: A Phase 1, Open-Label, Multicenter, Single Arm, Dose-Escalation/Dose-Expansion Study of YBL-006 in Patients with Advanced Solid Tumors
Sabanathan, D., Park, J., Gurney, H., Chapman, N. & Rai, M.
1/06/20 → 30/04/23
Project: Research
-
COSMIC: A randomized, double-blind, controled phase 3 study of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in subjects with previously untreated advanced or metastatic renal cell carcinoma of intermediate to poor risk
Gurney, H., Butala, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.
2/10/19 → 11/07/24
Project: Other
Research Outputs
-
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer
Sternberg, C. N., Saad, F., Graff, J. N., Peer, A., Vaishampayan, U. N., Leung, E., Rosenbaum, E., Gurney, H., Epstein, R. J., Davis, I. D., Wu, B., Trandafir, L., Wagner, V. J. & Hussain, M., 1 Feb 2020, In : Annals of Oncology. 31, 2, p. 257-265 9 p.Research output: Contribution to journal › Article
Open AccessFile2 Citations (Scopus)3 Downloads (Pure) -
Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma
Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., Kalofonos, H., Radulović, S., Demey, W., Ullén, A., Loriot, Y., Sridhar, S. S., Tsuchiya, N., Kopyltsov, E., Sternberg, C. N., Bellmunt, J., Aragon-Ching, J. B., Petrylak, D. P., Laliberte, R., Wang, J. & 7 others, , 24 Sep 2020, In : New England Journal of Medicine. 383, 13, p. 1218-1230 13 p.Research output: Contribution to journal › Article
7 Citations (Scopus) -
Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasma
Bhatnagar, A., McKay, M. J., Arasaratnam, M., Crumbaker, M., Gurney, H. & Molloy, M. P., Oct 2020, In : Journal of Mass Spectrometry. 55, 10, p. 1-8 8 p., e4584.Research output: Contribution to journal › Article
-
Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics
Nath, C. E., Trotman, J., Nivison-Smith, I., Gurney, H., Zeng, L., Presgrave, P., Tiley, C., Joshua, D., Kerridge, I., McLachlan, A. J. & Shaw, P. J., Sep 2020, In : Bone Marrow Transplantation. 55, 9, p. 1862-1864 3 p.Research output: Contribution to journal › Letter
-
Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés
Albiges, L., Tannir, N., Burotto, M., Mcdermott, D., Plimack, E., Barthélémy, P., Porta, C., Powles, T., Donskov, F., George, S., Kollmannsberger, C., Gurney, H., Grimm, M., Tomita, Y., Castellano, D., Rini, B., Choueiri, T., Shally Saggi, S., Mchenry, M. & Motzer, R., 1 Nov 2020, In : Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 30, 13, p. 785-786 2 p., CO-150.Research output: Contribution to journal › Meeting abstract